PP01.40 Target Lesion Response and Outcomes in Patients Treated with Brigatinib vs Crizotinib in ALTA-1L

D Ross Camidge,H. Ryun Kim,M.J. Ahn,James CH. Yang,J.-Y. Han,M.J. Hochmair, K.H. Lee,A. Delmonte,M.R. Garcia Campelo,D.-W. Kim,F. Griesinger,E. Felip,R. Califano,A.I. Spira,M. Thomas,S.N. Gettinger,M. Tiseo,Y. Liu,P. Zhang,S. Popat

Journal of Thoracic Oncology（2023）

引用 0|浏览12

暂无评分

摘要

In ALTA (NCT02094573), depth of target lesion response to brigatinib correlated with PFS and OS in patients with crizotinib-refractory advanced ALK+ NSCLC. We evaluated the association between maximum decrease in target lesions and PFS and OS in patients with ALK inhibitor-naive advanced ALK+ NSCLC from ALTA-1L (NCT02737501).

查看译文

关键词

brigatinib,crizotinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要